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Abstract. Objective and design: Excessive synovial fibrob-
last (SF) proliferation is detrimental in rheumatoid arthritis. 
We therefore sought to determine the effects of A77 1726, 
the active metabolite of leflunomide, on SF proliferation. 
Methods: Human SFs were used. Cell proliferation was in-
vestigated using MTS assay, by 3H-thymidine incorporation 
and cell counts. 
Results: Whereas A77 1726 alone had no effects, it signifi-
cantly increased the mitogenic effects of interleukin-1b (IL-
1b) and tumor necrosis factor-a (TNF-a). Cyclooxygenase 
inhibition might be at least partly involved, since indometh-
acin displayed similar effects, and since prostaglandin E2 
inhibited SF proliferation. In contrast, the effect of A77 1726 
did not appear to be mediated through depletion of the pyri-
midine pool or inhibition of tyrosine kinases. 
Conclusion: A77 1726 displays proliferative effects in pres-
ence of IL-1b and TNF-a. Further elucidation of involved 
mechanisms may prove useful for the utilization of lefluno-
mide, the development of related compounds or elaboration 
of new therapeutic strategies.
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Introduction
Leflunomide is a new oral disease-modifying anti-rheumatic 
drug (DMARD) approved for the treatment of rheumatoid 
arthritis (RA). The FDA approval was based on the results of 
three large phase III clinical trials that showed efficacy and 
safety to be nearly identical to methotrexate and significantly 
superior to placebo in particular for retardation of joint dam-
age (for review see [1]). Moreover, leflunomide significantly 
improved health-related quality of life and functional ability 
as compared with methotrexate [2].
Leflunomide is an immunomodulatory and anti-inflam-
matory agent that acts through its biologically active me-
tabolite, A77 1726. After oral administration, leflunomide 
is rapidly, non-enzymatically and completely converted into 
its long-acting, active metabolite A77 1726. Serum levels 
of A77 1726 in patients with rheumatoid arthritis treated 
with leflunomide shows large variability in the range of 
3–176 mg/L (15–750 µM) [3, 4]. A77 1726 is known to ex-
ert three distinct effects. At low doses, it reversibly inhibits 
dihydroorotate dehydrogenase (DHODH), which catalyzes 
the rate-limiting step in the de novo synthesis of pyrimidines 
(for review see [5]). This effect is likely responsible for the 
immunomodulatory effect of leflunomide in vivo. Indeed, 
unlike most other cells, activated T lymphocytes expand 
their pyrimidine pool by approximately eightfold during 
proliferation [6]. To meet this demand, lymphocytes use 
both salvage and de novo synthesis pathways. Inhibition 
of DHODH by A77 1726 thus prevents the accumulation 
of sufficient pyrimidines to support DNA synthesis. This 
effect of leflunomide can be reversed in vitro by addition of 
uridine to the culture medium [7]. The second known effect 
of leflunomide is inhibition of cyclooxygenase (COX) activ-
ity, both in vitro and in vivo [8]. Finally, at higher doses, 
leflunomide also inhibits tyrosine kinases. Indeed, A77 1726 
has been shown to inhibit the activities of the src related ty-
rosine kinases p56lck and p59fyn in Jurkat T cells [9], and 
interleukin-2 signaling through blockage of Jak1 and Jak3 
phosphorylation [10].
RA is characterized by the thickening of synovial tissue 
due to increased proliferation of synovial cells and infiltra-
tion of inflammatory cells such as lymphocytes and macro-
phages. Synovial fibroblasts (SFs) and macrophages secrete 
proteases and factors that are responsible for the degradation 
of articular cartilage and bone erosion [11]. Many studies 
indicate that SFs play a major role in cartilage destruction, Correspondence to: P.-A. Guerne
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and thus in the pathogenesis of RA [12, 13]. A77 1726 could 
potentially modulate SF proliferation through its three re-
ported effects: depletion of pyrimidine pools necessary for 
DNA synthesis, inhibition of src tyrosine kinase activity that 
signals SF proliferation during RA [14], and inhibition of 
COX activity [15], which may affect SF survival [16]. In this 
context, we aimed at determining the effects of A77 1726 
on synovial fibroblast proliferation. These experiments were 
performed both in absence and presence of IL-1b and TNF-a 
because these cytokines are widely recognized to be deeply 
involved in the development of RA and to increase SF pro-
liferation (reviewed in [17]). 
Materials and methods
Materials 
A77 1726 (HMR1726), the active metabolite of leflunomide, was kindly 
provided by Aventis Pharma (Frankfurt am Main, Germany). A77 1726 
was dissolved as a 10 mM stock solution in phosphate buffered saline. 
Cell culture reagents were obtained from Gibco (Life Technologies AG, 
Basel, Switzerland). Recombinant human IL-1b and TNF-a were pur-
chased from R&D Systems (Abington, United Kingdom). Uridine and 
prostaglandin E2 (PGE2) were obtained from Sigma Fine Chemicals 
(St. Louis, MO). The tyrosine kinase inhibitors genistein and PP1 were 
purchased from Calbiochem (Lucerne, Switzerland). 3H-thymidine was 
obtained from Amersham International (Little Chalfont, United King-
dom). The Cell Titer 96 Aqueus Non-Radioactive cell proliferation as-
say was obtained from Promega (Wallisellen, Switzerland).
Culture conditions
Synovium was obtained from patients undergoing joint replacement 
(knee or hip prosthetic surgery) for osteoarthritis (OA) or RA. A proto-
col for the use of synovial fibroblasts from patients undergoing articular 
replacement is currently submitted to the Ethics Committee of the Uni-
versity Hospital of Geneva. SFs were isolated by collagenase digestion 
as reported previously [18], and cultured in DMEM supplemented with 
L-glutamine, streptomycin, penicillin and 10 % heat-inactivated fetal 
calf serum at 37 °C in a humidified atmosphere containing 5 % CO2. 
Cells were used between passages 1 and 10, since in past studies and in 
this work, we did not observe differences in cell responsiveness in these 
conditions [18–20]. To first estimate cell proliferation with the Cell 
Titer 96 Aqueus Non-Radioactive Cell Proliferation Assay, 40,000 cells 
per well were grown in 96-well plates. Cell number was studied after 
trypan blue staining of cells grown in 24-well plates (12,500 cells per 
well) and 3H-thymidine incorporation was measured on cells in 96-well 
plates (5,000 cells per well). Cells were treated with IL-1b and/or TNF-
a for four days and, to investigate the effects of A77 1726 on stimulated 
SFs, cells were treated for 2 h with various concentrations of A77 1726 
before addition of cytokines. Since we previously observed that at 
100 µM, A77 1726 had maximal beneficial effects on IL-1Ra production 
with 1 ng/ml IL-1b and 10 ng/ml TNF-a levels [19], we used the same 
concentrations, which are in the range of concentrations used in in vitro 
experiments on synovial fibroblast biology. Moreover, to decipher the 
mechanisms involved in the effects of A77 1726, we also treated cells 
with the COX inhibitor indomethacin (5 µg/ml), and the tyrosine kinase 
inhibitors genistein (0.1 to 50 µM) and PP1 (1 to 25 µM) 2 h before IL-1b 
and/or TNF-a treatment. 
In order to check the bioactivity of A77 1726, we measured its ef-
fects on Jurkat T cell proliferation, as previously reported [21]. Briefly, 
Jurkat T cells were grown in RPMI 1640 containing 10 % heat-inacti-
vated fetal calf serum at 37 °C in a humidified atmosphere containing 
5 % CO2. To analyze cell proliferation in response to A77 1726, 20,000 
cells per well were incubated in presence of 0.5 % FCS in 96-well plates. 
Cells were then treated with various concentrations of A77-1726 with 
or without 5 µM uridine for 48 h, before 3H-thymidine addition for the 
next 6 h.
Cell proliferation
In a first attempt to assess cell proliferation, we used the CellTiter 96 
Aqueus Non-Radioactive Cell Proliferation Assay, where the formation 
of formazan from methyltetrazolium salt (MTS) is quantified by colori-
metric measurement at 490 nm. Moreover, to assess cell numbers, cells 
were harvested by digestion with trypsin and viable cells, identified by 
trypan blue exclusion were counted under a contrast-phase microscope. 
SF proliferation was also investigated by measuring 3H-Thymidine up-
take. SFs were treated for 4 days before the cultures were pulsed with 
3H-Thymidine (1 µCi per well) for 18 h. SFs were then washed and lysed 
by adding 100 µl NaOH 0.1M into each well, and the cell lysates were 
transferred into liquid scintillation vials. Non-adherent Jurkat cells were 
grown for 2 days before addition of 3H-Thymidine (1 µCi per well) for 
6 h as previously described. Jurkat cells were then harvested on glass fil-
ter paper using a multi-well automated cell harvester (Skatron, Sterling, 
VA) and the filters were placed into vials. Radioactivity was quantified 
by liquid scintillation counting. 
Statistical analysis
Significance of differences was calculated by ANOVA. A difference 
between experimental groups was considered significant when the p 
value was <0.05.
Results
In the present experiments, we observed no differences 
related to synovial fibroblast source, i.e. osteoarthritis or 
rheumatoid arthritis, or to cell passage.
A77 1726 stimulates SF proliferation in presence of IL-1b 
and/or TNF-a
In a first effort to investigate the effects of A77 1726 on 
SF behavior, we measured MTS conversion after 4 days 
of treatment in presence of IL-1b and TNF-a. The results 
showed that IL-1b and TNF-a increased MTS activity 
in cultures of SFs (Fig. 1A), according to their known 
mitogenic effect on these cells. A77 1726 inhibited both 
the baseline MTS activity and the activity stimulated by 
cytokines when added at a final concentration of 100 µM, 
which is in the range of plasma concentrations in humans 
at a steady-state under daily doses of 20 mg [4, 22–24]. 
We then performed cell counts to examine whether this 
decrease in MTS activity was accompanied by a decrease in 
cell number. The results indicated that the cell number was 
elevated after 4 days of treatment with IL-1b and TNF-a, 
but surprisingly was further increased by 100 µM A77 1726 
(Fig. 1B). Therefore, to ascertain whether these effects 
of A77 1726 on cell counts were due to a stimulation of 
proliferation, we next investigated the effects of A77 1726 
on 3H-thymidine incorporation by SFs. We observed that 
A77 1726 increased the stimulatory effects of IL-1b and 
TNF-a on SF 3H-thymidine incorporation (Fig. 1C). The 
dose response analysis indicated that A77 1726 exerted 
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with 25 and 50 µM A77 1726, and this effect was significantly 
blocked by addition of 5 µM uridine (Fig. 3). 
The mitogenic effect of A77 1726 on SFs is not reversed by 
addition of exogenous uridine 
To examine the mechanisms involved in the stimulation of 
SF proliferation by A77 1726, we analyzed, with regards to 
SF proliferation, the three reported effects on lefunomide: 
inhibition of DHODH, inhibition of tyrosine kinase activity, 
and inhibition of COX activity. We first investigated whether 
addition of exogenous uridine (5 to 200 µM) could reverse 
the stimulation of proliferation by A77 1726 in presence of 
maximal effects at 100 µM and increased the mitogenic 
effects of IL-1b and TNF-a, used alone and in combination 
(Fig. 2). A decrease in 3H-thymidine incorporation was 
observed with 200 and 300 µM of A77 1726, which likely 
resulted from toxicity, since we observed a loss of cell 
attachment after 4 days of treatment with these high doses. 
Consequently, we performed the next experiments on SF 
proliferation with 100 µM of A77 1726.
Inhibition of Jurkat T cell proliferation by A77 1726 is 
reversed by addition of exogenous uridine
We then checked whether, as demonstrated previously 
[21], A77 1726 decreases Jurkat T cell proliferation in our 
hands, and whether this decrease is reversed by the addition 
of exogenous uridine to the culture medium. Indeed we 
observed a down-regulation of Jurkat T cell proliferation 
Fig. 1. A77 1726 increases SF proliferation in presence of IL-1b and 
TNF-a. Human SFs were stimulated or not with 1 ng/ml IL-1b, 10 ng/
ml TNF-a and 100 µM A77 1726 for 4 days. A77 1726 was added 2 h 
prior to stimulation with cytokines. MTS conversion (A), cell counts 
(B) and 3H-thymidine incorporation (C) were determined as detailed in 
the materials and methods section. Results are expressed in percentage 
of variation as compared with control. Each bar represents the mean 
+SEM of triplicate cultures of a representative experiment. *P < 0.05 as 
compared with control; **P < 0.05 as compared with IL-1b and TNF-a 
treated cells.
Fig. 2. A77 1726 dose-dependently increases SF proliferation in pres-
ence of IL-1b, TNF-a or both. Human SFs were stimulated or not with 
1 ng/ml IL-1b, 10 ng/ml TNF-a or both, in combination with various 
concentrations of A77 1726 for 4 days. A77 1726 was added 2 h prior to 
stimulation with cytokines. 3H-thimidine incorporation was quantified 
as detailed in the materials and methods section. Each bar represents 
the mean +SEM of triplicate cultures of a representative experiment. 
*P < 0.05 as compared with control; **P < 0.05 as compared with cells 
treated with the corresponding cytokine combination. 
Fig. 3. Inhibition of Jurkat T cell proliferation by A77 1726 is reversed 
by exogenous uridine. Jurkat T cells were treated with various doses 
of A77 1726 and/or 5 µM uridine for 48 h. Uridine was added 2 h prior 
to A77 1726 treatment. 3H-thimidine incorporation was quantified as 
detailed in the materials and methods section. Each bar represents the 
mean +SEM of triplicate cultures of a representative experiment. *P 
< 0.05 as compared with control; **P < 0.05 as compared with cells 
treated with the corresponding A77-1726 dose. 
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IL-1b or TNF-a, but we did not observe any inhibition of 
A77 1726 effects (data not shown).
Inhibition of tyrosine kinases blocks IL-1b- and TNF-a-
induced SF proliferation 
Leflunomide has been shown to inhibit several receptor 
and non-receptor tyrosine kinases (for review see [5]), 
particularly those of the src family [9], which are involved 
in SF proliferation during RA in vivo [14]. Because IL-1b 
signaling involves activation of the src tyrosine kinase, we 
first studied the effect of the specific src tyrosine kinase 
inhibitor PP1 on SF treated with IL-1b. Results showed 
that PP1, at concentrations of 1 µM or higher, blocked 
the thymidine incorporation induced by IL-1b (Fig. 4A). 
Involvement of tyrosine kinases in IL-1b-stimulated 
SF proliferation was confirmed by the inhibition of 3H-
thymidine incorporation by genistein at concentrations of 
0.1 µM or higher (Fig. 4B). Finally, genistein also inhibited 
the increase in 3H-thymidine incorporation induced by 
TNF-a (Fig. 4C), suggesting that tyrosine kinases are 
also involved in mediating the effects of TNF-a on SF 
proliferation. Taken together, these observations indicate 
that A77 1726 is very unlikely to increase 3H-thymidine 
incorporation by inhibiting tyrosine kinases.
Inhibition of COX increases the mitogenic effects of IL-1b 
and TNF-a
Because leflunomide was reported to block COX activity 
in SF cultures [15], we investigated the effects of COX 
inhibition on SF proliferation. We used 5 µg/ml of 
indomethacin since we observed that this concentration 
completely inhibits PGE2 production by SFs [19]. Figure 
5 indicates that indomethacin, like A77 1726, increased 
3H-thymidine incorporation in presence of IL-1b or TNF-
a (Fig. 5). Accordingly, PGE2, one of the prostaglandins 
synthesized by the COX, dose-dependently decreased 
SF proliferation in absence of IL-1b and TNF-a (Fig. 6). 
However, in the presence of inflammatory cytokines and 
Fig. 4. Inhibition of tyrosine kinases blocks IL-1b- or TNF-a-stimulated 
SF proliferation. Human SFs were stimulated or not for 4 days with 1 ng/
ml IL-1b (A and B) or 10 ng/ml TNF-a (C), in combination with various 
levels of PP1 (A) or genistein (B). Genistein or PP1 were added 2 h prior 
to stimulation with cytokines. 3H-thimidine incorporation was quantified 
as detailed in the materials and methods section. Each bar represents 
the mean +SEM of triplicate cultures of a representative experiment. 
*P < 0.05 as compared with control; **P < 0.05 as compared with cells 
treated with the corresponding cytokine.
Fig. 5. Inhibition of COX mimics A77 1726 effects on SF stimulated 
with IL-1b or TNF-a. Human SFs were stimulated or not for 4 days 
with 1 ng/ml IL-1b (A) or 10 ng/ml TNF-a (B), in absence or pres-
ence of 5 µg/ml of indomethacin. Indomethacin was added 2 h prior to 
stimulation with cytokines. 3H-thimidine incorporation was quantified 
as detailed in the materials and methods section. Each bar represents 
the mean +SEM of triplicate cultures of a representative experiment. 
*P < 0.05 as compared with control; **P < 0.05 as compared with cells 
treated with the corresponding cytokine.
Fig. 6. PGE2 dose-dependently decreases SF proliferation. Human SFs 
were stimulated or not for 4 days with 10 to 1,000 ng/ml of PGE2. 3H-
thimidine incorporation was quantified as detailed in the materials and 
methods section. Each bar represents the mean +SEM of triplicate cul-
tures of a representative experiment. *P < 0.05 as compared with con-
trol; **P < 0.05 as compared with cells treated with 10 ng/ml PGE2.
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A77 1726, addition of PGE2 did not reverse the effects of 
A77 1726 (data not shown).
Discussion
RA is characterized by invasive synovial hyperplasia 
which plays an important role in the mechanisms leading 
to progressive joint destruction. SFs manifest an abnormal 
phenotype illustrated by increased proliferation, resistance to 
apoptosis, and invasiveness of cartilage and bone. They also 
produce elevated amounts of pro-inflammatory cytokines 
[25] and proteases, and induce osteoclast formation and 
activation [26]. Although a recent study showed that 
cartilage invasion does not depend directly on synoviocyte 
proliferation [27], overgrowth of the synovial bulk and lack 
of synovial cell apoptosis are nevertheless thought to play a 
very important role in the pathogenesis of RA. Thus, cartilage 
and bone degradation occurring during the progression of RA 
could be greatly reduced by the inhibition of SF proliferation 
[14]. In this study, we sought to determine the effects of 
A77 1726, the active metabolite of leflunomide, on SF 
proliferation. A77 1726 has already been shown to display 
a large array of biological effects on SF behavior: it inhibits 
the production of IL-1b, TNF-a [28], IL-6 [15], nitric oxide 
[28], PGE2 [15], matrix metalloproteinase-1 [15] and matrix 
metalloproteinase-3 [28], whereas it increases that of IL-1 
receptor antagonist [19]. It appeared reasonable to postulate 
that A77 1726 might also modulate SF proliferation through 
inhibition of pyrimidine synthesis, of tyrosine kinase and/or 
of COX activities. To investigate A77 1726 effects, we used 
concentrations known to be present in the serum of patients 
treated with leflunomide [3]. Similar concentrations are 
very likely to present in the synovial fluid as well, given the 
rich vascularization and extremely high permeability of the 
synovial membrane.
Surprisingly, our results indicate that leflunomide 
increases SF proliferation in presence of IL-1b and/or 
TNF-a. This is in contrast with a previous study suggesting 
that leflunomide had no effect on cell viability in culture of 
synovial tissue [28]. It is unlikely that these discrepancies 
are due to differences in cell origin, since we observed 
similar results when SFs from patients with RA or OA were 
used. They may not be due to cell passage either, because 
A77 1726 stimulated SF proliferation independently from 
passage in our study; and since in addition, the passage 
did not significantly modify SF responsiveness to several 
cytokines in our previous investigations [18–20]. Actually, 
the previous report suggesting that leflunomide had no effect 
on cell proliferation was performed with an assay based 
on tetrazolium salt reduction, which measures the activity 
of a variety of enzymes, located not only in mitochondria, 
but also in other cellular compartments [29]. In the present 
study, we observed a discrepancy between results obtained 
when measuring MTS conversion, as compared to thymidine 
incorporation and cell counts. The dose-dependent decrease 
in MTS conversion induced by A77 1726, which we observed 
both in absence and presence of inflammatory cytokines, 
appears to be due to inhibition by A77 1726 of one or several 
enzymes responsible for MTS reduction, with no direct 
relation to cell proliferation. Therefore, determination of the 
effects of leflunomide on cell proliferation using tetrazolium 
salt assays must be considered with much caution. 
Because our results indicating that A77 1726 did not 
inhibit SF proliferation were unexpected, we checked the 
effects of A77 1726 on Jurkat T cell proliferation. We 
confirmed that A77 1726 inhibits proliferation of Jurkat T 
cells and that this effect is reversed by addition of uridine 
[21]. Blockage of the de novo pyrimidine synthesis pathway 
through DHODH inhibition by A77 1726 thus inhibits cell 
division of the highly proliferating Jurkat T cells [21]. In 
contrast SFs, like other cell types, may maintain sufficient 
pyrimidine levels to meet their requirements for cell division 
through the use of salvage pathways and are thus not 
affected by DHODH inhibition [24]. However, if the fact 
that A77 1726 does not inhibit SF proliferation in absence 
of IL-1b or TNF-a can be explained by the utilization of 
salvage pathways, the significant increase in proliferation 
induced by A77 1726 in presence of IL-1b and TNF-a 
appears surprising. 
Inhibition of tyrosine kinases is unlikely to be involved 
in the stimulation of proliferation by A77 1726 because 
inhibitors of tyrosine kinases blocked the proliferation 
induced by IL-1b or by TNF-a. In addition, IL-1b likely 
stimulates SF proliferation through activation of the src 
tyrosine kinase pathway [14], likewise we also observed 
that the specific src tyrosine kinase inhibitor PP1 reduced SF 
proliferation induced by IL-1b. The mitogenic stimulation 
of A77 1726 thus likely arises from other mechanisms than 
inhibition of tyrosine kinase activity. We next explored 
the known effect of leflunomide on COX inhibition [8], 
because we recently showed that both 100 µM A77 1726 and 
5 µg/ml indomethacin completely inhibited the production 
of PGE2 induced by IL-1b in synovial fibroblasts [19]. 
In the present study, we observed that indomethacin 
increased the mitogenic effects of IL-1b and/or those of 
TNF-a, suggesting that A77 1726 might indeed display its 
proliferative effects by inhibiting COX. Accordingly, PGE2 
dose-dependently inhibited SF proliferation. However, 
in presence of IL-1b or TNF-a, we could not observe 
an inhibition of A77 1726 effects by PGE2. This finding 
may be due to the fact that other prostaglandins or factors 
modulated by COX are induced by inflammatory cytokines 
and alter SF proliferation. Moreover, as previously observed 
for the induction of IL-1Ra production by A77 1726 in SFs, 
relatively high doses of A77 1726 (100 µM) were required to 
efficiently increase cell proliferation, while IL-1b-induced 
PGE2 production is inhibited already at relatively lower 
concentrations (10–50 µM) [19]. The dose dependencies 
of the two effects thus appeared to be slightly different. 
Nevertheless, it is conceivable that A77 1726 increases SF 
proliferation at least in part through inhibition of COX and 
prostaglandin synthesis. This would be consistent with the 
fact that A77 1726 displayed significant mitogenic effects 
in the presence of IL-1b or TNF-a, which both induce 
high levels of prostaglandins, but not in their absence. 
On the other hand, we cannot exclude the possibility that 
leflunomide, as well as indomethacin, exerts proliferative 
effects by yet unknown distinct mechanisms. 
Whether this in vitro mitogenic effect of A77 1726 on SF 
proliferation translates into significant synovial proliferation 
in patients is still unknown but deserves consideration. 
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Recently, an analysis by dynamic gadolinium enhanced 
magnetic resonance imaging (DEMRI) of synovial tissue 
in patients with RA treated with leflunomide, showed a 
significant reduction in the initial rate of enhancement and 
maximal enhancement [30]. DEMRI provides a measure 
of blood perfusion, capillary permeability and extracellular 
volume, all of which reflect the inflammatory process of 
synovitis. DEMRI also correlates with the infiltrating leuco-
cytes in the RA synovial tissue. A reduction in the number 
of macrophages was indeed observed in synovial tissue 
samples obtained from patients with RA after four months’ 
treatment with leflunomide [31]. It may therefore be hypoth-
esized that leflunomide exerts its beneficial effects during 
RA mainly through its immunomodulatory and anti-inflam-
matory action on lymphocytes and monocytes/macrophages, 
which in turn may contribute to reduce synovial fibroblast 
activation and proliferation. Finally, it is also conceivable 
that like in serum [4, 22], A77 1726 levels in the vicinity 
of the synovial fibroblast exceed 100 µM, and reach 200 or 
300 µM, concentrations that do not increase proliferation. 
However, evidence is lacking to support this hypothesis and 
today there is still uncertainty as whether the serum level of 
A77 1726 is correlated with disease activity [4, 22].
There is no doubt that leflunomide is extremely efficient 
in RA, as well as in other inflammatory arthropathies 
including psoriatic arthritis [32, 33]. In RA, leflunomide’s 
efficacy was shown to be comparable to that of methotrexate 
with effects reported to be more rapid and slightly better 
with regards to functional outcome at two years radiological 
progression [2, 34]. This places leflunomide as one of the 
best non-biological agents available for the treatment of RA 
[35, 36]. 
Our results, though, indicate that the array of beneficial 
effects exerted by leflunomide could be partly lessened 
by an inducing effect on SF proliferation. It might be that 
this latter effect is not significant or that it is annihilated by 
the other, beneficial, activities of leflunomide, including 
inhibition of IL-1b and TNF-a synthesis [28], and increase 
in IL-1Ra production [19] (IL-1b and TNF-a are strong 
stimulators of SF proliferation). It might also be, however, 
that in some cases the progressive increase of the synovial 
bulk could be detrimental on the long term; if substantiated, 
it would warrant modified treatment strategies, which could 
include associated use of pro-apoptotic or anti-proliferative 
agents. Alternatively, efforts directed at developing related 
pharmacological compounds, devoid of this detrimental 
effect, would be justified. In any event, we believe that the 
unexpected observation that leflunomide is able to decrease 
the proliferation of multiple cell types while increasing that 
of SFs, is biologically of interest.
In conclusion, results of the present study indicate 
that the active metabolite of leflunomide, A77 1726, at 
therapeutically applicable doses, stimulates the proliferation 
of synovial fibroblasts in the presence of the inflammatory 
cytokines IL-1b and TNF-a, and that this effect could 
be related to COX activity. This may lessen the beneficial 
effect of leflunomide in the treatment of RA, and therefore 
further elucidation of involved mechanisms may prove 
useful for the utilization of leflunomide, the development 
of related compounds or elaboration of new therapeutic 
strategies.
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